blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2639240

EP2639240 - Peptides able to impair the inhibiting activity of MDM2/MDM4 heterodimer towards p53 and use thereof for cancer treatment [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  28.04.2017
Database last updated on 18.11.2024
Most recent event   Tooltip06.03.2020Lapse of the patent in a contracting state
New state(s): TR		published on 08.04.2020  [2020/15]
Applicant(s)For all designated states
Consiglio Nazionale Delle Ricerche
Piazzale Aldo Moro, 7
00185 Roma / IT
For all designated states
Universita Degli Studi Di Perugia
Piazza dell' Universita N.1
06123 Perugia / IT
[2013/38]
Inventor(s)01 / Pellegrino, Marsha
Istituto di Biologia Cellulare e Neurobiologia
Via del Fosso di Fiorano 64
00143 Roma / IT
02 / Moretti, Fabiola
Istituto di Biologia Cellulare e Neurobiologia
Via del Fosso di Fiorano 64
00143 Roma / IT
03 / Mancini, Francesca
Istituto di Biologia Cellulare e Nerobiologia
Via del Fosso di Fiorano 64
00143 Roma / IT
04 / Macchiarulo, Antonio
Dipartimento di Chimica e Tecnologia del Farmaco
Via del Liceo 1
06123 Perugia / IT
05 / Pellicciari, Roberto
Dipartimento di Chimica e Tecnologia del Farmaco
Via del Liceo 1
06123 Perugia / IT
 [2016/25]
Former [2013/38]01 / Pellegrino, Marsha
Istituto di Biologia Cellulare e Neurobiologia
Via del Fosso di Fiorano 64
00143 Roma / IT
02 / Moretti, Fabiola
Istituto di Biologia Cellulare e Neurobiologia
Via del Fosso di Fiorano 64
00143 Roma / IT
03 / Mancini, Francesca
Istituto di Biologia Cellulare e Nerobiologia
Via del Fosso di Fiorano 64
00143 Roma / IT
04 / Macchiarulo, Antonio
Dipartimento di Chimica e Tecnologia del Farmaco
Via del Liceo 1
06123 Perugia / IT
05 / Pelliciari, Roberto
Dipartimento di Chimica e Tecnologia del Farmaco
Via del Liceo 1
06123 Perugia / IT
Representative(s)Gitto, Serena, et al
Barzanò & Zanardo Roma S.p.A.
Via Piemonte, 26
00187 Roma / IT
[2016/25]
Former [2013/38]Gitto, Serena, et al
Barzanò & Zanardo Roma S.p.A. Via Piemonte, 26
00187 Roma / IT
Application number, filing date13155985.820.02.2013
[2013/38]
Priority number, dateIT2012RM0006021.02.2012         Original published format: IT RM20120060
[2013/38]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP2639240
Date:18.09.2013
Language:EN
[2013/38]
Type: A3 Search report 
No.:EP2639240
Date:04.12.2013
Language:EN
[2013/49]
Type: B1 Patent specification 
No.:EP2639240
Date:22.06.2016
Language:EN
[2016/25]
Search report(s)(Supplementary) European search report - dispatched on:EP05.11.2013
ClassificationIPC:C07K14/47
[2013/38]
CPC:
C07K14/47 (EP,US); C07K7/08 (US); A61K38/00 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/25]
Former [2013/38]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:Peptide zur Beeinträchtigung der Hemmung der Aktivität von MDM2/MDM4-Heterodimer zu p53 und Verwendung davon zur Krebsbehandlung[2013/38]
English:Peptides able to impair the inhibiting activity of MDM2/MDM4 heterodimer towards p53 and use thereof for cancer treatment[2013/38]
French:Peptides capables de neutraliser l'activité d'inhibition d'une hétérodimère MDM2/MDM4 vers p53 et leur utilisation pour le traitement du cancer[2013/38]
Examination procedure03.06.2014Amendment by applicant (claims and/or description)
03.06.2014Examination requested  [2014/29]
22.01.2016Communication of intention to grant the patent
11.05.2016Fee for grant paid
11.05.2016Fee for publishing/printing paid
11.05.2016Receipt of the translation of the claim(s)
07.06.2016Request for correction of the decision to grant filed
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  22.01.2016
Opposition(s)23.03.2017No opposition filed within time limit [2017/22]
Fees paidRenewal fee
16.02.2015Renewal fee patent year 03
23.02.2016Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU20.02.2013
AL22.06.2016
AT22.06.2016
BE22.06.2016
BG22.06.2016
CY22.06.2016
CZ22.06.2016
DK22.06.2016
EE22.06.2016
ES22.06.2016
FI22.06.2016
HR22.06.2016
IT22.06.2016
LT22.06.2016
LV22.06.2016
MC22.06.2016
MK22.06.2016
NL22.06.2016
PL22.06.2016
RO22.06.2016
RS22.06.2016
SE22.06.2016
SI22.06.2016
SK22.06.2016
SM22.06.2016
TR22.06.2016
NO22.09.2016
GR23.09.2016
IS22.10.2016
PT24.10.2016
GB20.02.2017
IE20.02.2017
LU20.02.2017
MT20.02.2017
CH28.02.2017
FR28.02.2017
LI28.02.2017
[2020/15]
Former [2019/51]HU20.02.2013
AL22.06.2016
AT22.06.2016
BE22.06.2016
BG22.06.2016
CY22.06.2016
CZ22.06.2016
DK22.06.2016
EE22.06.2016
ES22.06.2016
FI22.06.2016
HR22.06.2016
IT22.06.2016
LT22.06.2016
LV22.06.2016
MC22.06.2016
MK22.06.2016
NL22.06.2016
PL22.06.2016
RO22.06.2016
RS22.06.2016
SE22.06.2016
SI22.06.2016
SK22.06.2016
SM22.06.2016
NO22.09.2016
GR23.09.2016
IS22.10.2016
PT24.10.2016
GB20.02.2017
IE20.02.2017
LU20.02.2017
MT20.02.2017
CH28.02.2017
FR28.02.2017
LI28.02.2017
Former [2019/46]HU20.02.2013
AL22.06.2016
AT22.06.2016
BE22.06.2016
BG22.06.2016
CY22.06.2016
CZ22.06.2016
DK22.06.2016
EE22.06.2016
ES22.06.2016
FI22.06.2016
HR22.06.2016
IT22.06.2016
LT22.06.2016
LV22.06.2016
MC22.06.2016
NL22.06.2016
PL22.06.2016
RO22.06.2016
RS22.06.2016
SE22.06.2016
SI22.06.2016
SK22.06.2016
SM22.06.2016
NO22.09.2016
GR23.09.2016
IS22.10.2016
PT24.10.2016
GB20.02.2017
IE20.02.2017
LU20.02.2017
MT20.02.2017
CH28.02.2017
FR28.02.2017
LI28.02.2017
Former [2019/39]HU20.02.2013
AL22.06.2016
AT22.06.2016
BE22.06.2016
BG22.06.2016
CZ22.06.2016
DK22.06.2016
EE22.06.2016
ES22.06.2016
FI22.06.2016
HR22.06.2016
IT22.06.2016
LT22.06.2016
LV22.06.2016
MC22.06.2016
NL22.06.2016
PL22.06.2016
RO22.06.2016
RS22.06.2016
SE22.06.2016
SI22.06.2016
SK22.06.2016
SM22.06.2016
NO22.09.2016
GR23.09.2016
IS22.10.2016
PT24.10.2016
GB20.02.2017
IE20.02.2017
LU20.02.2017
MT20.02.2017
CH28.02.2017
FR28.02.2017
LI28.02.2017
Former [2019/31]HU20.02.2013
AL22.06.2016
AT22.06.2016
BE22.06.2016
CZ22.06.2016
DK22.06.2016
EE22.06.2016
ES22.06.2016
FI22.06.2016
HR22.06.2016
IT22.06.2016
LT22.06.2016
LV22.06.2016
MC22.06.2016
NL22.06.2016
PL22.06.2016
RO22.06.2016
RS22.06.2016
SE22.06.2016
SI22.06.2016
SK22.06.2016
SM22.06.2016
NO22.09.2016
GR23.09.2016
IS22.10.2016
PT24.10.2016
GB20.02.2017
IE20.02.2017
LU20.02.2017
MT20.02.2017
CH28.02.2017
FR28.02.2017
LI28.02.2017
Former [2018/46]AL22.06.2016
AT22.06.2016
BE22.06.2016
CZ22.06.2016
DK22.06.2016
EE22.06.2016
ES22.06.2016
FI22.06.2016
HR22.06.2016
IT22.06.2016
LT22.06.2016
LV22.06.2016
MC22.06.2016
NL22.06.2016
PL22.06.2016
RO22.06.2016
RS22.06.2016
SE22.06.2016
SI22.06.2016
SK22.06.2016
SM22.06.2016
NO22.09.2016
GR23.09.2016
IS22.10.2016
PT24.10.2016
GB20.02.2017
IE20.02.2017
LU20.02.2017
MT20.02.2017
CH28.02.2017
FR28.02.2017
LI28.02.2017
Former [2018/43]AT22.06.2016
BE22.06.2016
CZ22.06.2016
DK22.06.2016
EE22.06.2016
ES22.06.2016
FI22.06.2016
HR22.06.2016
IT22.06.2016
LT22.06.2016
LV22.06.2016
MC22.06.2016
NL22.06.2016
PL22.06.2016
RO22.06.2016
RS22.06.2016
SE22.06.2016
SI22.06.2016
SK22.06.2016
SM22.06.2016
NO22.09.2016
GR23.09.2016
IS22.10.2016
PT24.10.2016
GB20.02.2017
IE20.02.2017
LU20.02.2017
MT20.02.2017
CH28.02.2017
FR28.02.2017
LI28.02.2017
Former [2018/13]AT22.06.2016
BE22.06.2016
CZ22.06.2016
DK22.06.2016
EE22.06.2016
ES22.06.2016
FI22.06.2016
HR22.06.2016
IT22.06.2016
LT22.06.2016
LV22.06.2016
MC22.06.2016
NL22.06.2016
PL22.06.2016
RO22.06.2016
RS22.06.2016
SE22.06.2016
SI22.06.2016
SK22.06.2016
SM22.06.2016
NO22.09.2016
GR23.09.2016
IS22.10.2016
PT24.10.2016
GB20.02.2017
IE20.02.2017
LU20.02.2017
CH28.02.2017
FR28.02.2017
LI28.02.2017
Former [2018/07]AT22.06.2016
BE22.06.2016
CZ22.06.2016
DK22.06.2016
EE22.06.2016
ES22.06.2016
FI22.06.2016
HR22.06.2016
IT22.06.2016
LT22.06.2016
LV22.06.2016
MC22.06.2016
NL22.06.2016
PL22.06.2016
RO22.06.2016
RS22.06.2016
SE22.06.2016
SI22.06.2016
SK22.06.2016
SM22.06.2016
NO22.09.2016
GR23.09.2016
IS22.10.2016
PT24.10.2016
LU20.02.2017
CH28.02.2017
FR28.02.2017
LI28.02.2017
Former [2018/04]AT22.06.2016
BE22.06.2016
CZ22.06.2016
DK22.06.2016
EE22.06.2016
ES22.06.2016
FI22.06.2016
HR22.06.2016
IT22.06.2016
LT22.06.2016
LV22.06.2016
MC22.06.2016
NL22.06.2016
PL22.06.2016
RO22.06.2016
RS22.06.2016
SE22.06.2016
SI22.06.2016
SK22.06.2016
SM22.06.2016
NO22.09.2016
GR23.09.2016
IS22.10.2016
PT24.10.2016
LU20.02.2017
CH28.02.2017
LI28.02.2017
Former [2017/51]AT22.06.2016
BE22.06.2016
CZ22.06.2016
DK22.06.2016
EE22.06.2016
ES22.06.2016
FI22.06.2016
HR22.06.2016
IT22.06.2016
LT22.06.2016
LV22.06.2016
MC22.06.2016
NL22.06.2016
PL22.06.2016
RO22.06.2016
RS22.06.2016
SE22.06.2016
SI22.06.2016
SK22.06.2016
SM22.06.2016
NO22.09.2016
GR23.09.2016
IS22.10.2016
PT24.10.2016
CH28.02.2017
LI28.02.2017
Former [2017/45]AT22.06.2016
BE22.06.2016
CZ22.06.2016
DK22.06.2016
EE22.06.2016
ES22.06.2016
FI22.06.2016
HR22.06.2016
IT22.06.2016
LT22.06.2016
LV22.06.2016
MC22.06.2016
NL22.06.2016
PL22.06.2016
RO22.06.2016
RS22.06.2016
SE22.06.2016
SI22.06.2016
SK22.06.2016
SM22.06.2016
NO22.09.2016
GR23.09.2016
IS22.10.2016
PT24.10.2016
Former [2017/38]AT22.06.2016
BE22.06.2016
CZ22.06.2016
DK22.06.2016
EE22.06.2016
ES22.06.2016
FI22.06.2016
HR22.06.2016
IT22.06.2016
LT22.06.2016
LV22.06.2016
NL22.06.2016
PL22.06.2016
RO22.06.2016
RS22.06.2016
SE22.06.2016
SI22.06.2016
SK22.06.2016
SM22.06.2016
NO22.09.2016
GR23.09.2016
IS22.10.2016
PT24.10.2016
Former [2017/11]AT22.06.2016
BE22.06.2016
CZ22.06.2016
EE22.06.2016
ES22.06.2016
FI22.06.2016
HR22.06.2016
IT22.06.2016
LT22.06.2016
LV22.06.2016
NL22.06.2016
PL22.06.2016
RO22.06.2016
RS22.06.2016
SE22.06.2016
SK22.06.2016
SM22.06.2016
NO22.09.2016
GR23.09.2016
IS22.10.2016
PT24.10.2016
Former [2017/10]BE22.06.2016
CZ22.06.2016
EE22.06.2016
FI22.06.2016
HR22.06.2016
IT22.06.2016
LT22.06.2016
LV22.06.2016
NL22.06.2016
PL22.06.2016
RO22.06.2016
RS22.06.2016
SE22.06.2016
SK22.06.2016
NO22.09.2016
GR23.09.2016
IS22.10.2016
Former [2017/09]CZ22.06.2016
EE22.06.2016
FI22.06.2016
HR22.06.2016
IT22.06.2016
LT22.06.2016
LV22.06.2016
NL22.06.2016
RO22.06.2016
RS22.06.2016
SE22.06.2016
NO22.09.2016
GR23.09.2016
Former [2016/52]FI22.06.2016
HR22.06.2016
LT22.06.2016
LV22.06.2016
NL22.06.2016
RS22.06.2016
SE22.06.2016
NO22.09.2016
GR23.09.2016
Former [2016/51]FI22.06.2016
HR22.06.2016
LT22.06.2016
LV22.06.2016
RS22.06.2016
NO22.09.2016
GR23.09.2016
Former [2016/50]FI22.06.2016
HR22.06.2016
LT22.06.2016
LV22.06.2016
RS22.06.2016
NO22.09.2016
Former [2016/49]FI22.06.2016
LT22.06.2016
NO22.09.2016
Former [2016/46]LT22.06.2016
NO22.09.2016
Documents cited:Search[XA]  - ZOE VASILEIOU ET AL, "Convergent solid-phase and solution approaches in the synthesis of the cysteine-rich Mdm2 RING finger domain", JOURNAL OF PEPTIDE SCIENCE, (20091201), vol. 15, no. 12, doi:10.1002/psc.1182, ISSN 1075-2617, pages 824 - 831, XP055040405 [X] 1,2 * the whole document * [A] 3,4,7-15

DOI:   http://dx.doi.org/10.1002/psc.1182
 [A]  - M. WADE ET AL, "Targeting Mdm2 and Mdmx in Cancer Therapy: Better Living through Medicinal Chemistry?", MOLECULAR CANCER RESEARCH, (20090101), vol. 7, no. 1, doi:10.1158/1541-7786.MCR-08-0423, ISSN 1541-7786, pages 1 - 11, XP055040406 [A] 1-4,7-15 * the whole document *

DOI:   http://dx.doi.org/10.1158/1541-7786.MCR-08-0423
 [A]  - WANG XINJIANG, "p53 regulation: teamwork between RING domains of Mdm2 and MdmX", CELL CYCLE, LANDES BIOSCIENCE, US, (20111215), vol. 10, no. 24, ISSN 1551-4005, pages 4225 - 4229, XP009163428 [A] 1-4,7-15 * the whole document *

DOI:   http://dx.doi.org/10.4161/cc.10.24.18662
 [A]  - K LINKE ET AL, "Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans", CELL DEATH AND DIFFERENTIATION, (20080501), vol. 15, no. 5, doi:10.1038/sj.cdd.4402309, ISSN 1350-9047, pages 841 - 848, XP055040408 [A] 1-4,7-15 * the whole document *

DOI:   http://dx.doi.org/10.1038/sj.cdd.4402309
 [A]  - R. K. SINGH ET AL, "Hetero-oligomerization with MdmX Rescues the Ubiquitin/Nedd8 Ligase Activity of RING Finger Mutants of Mdm2", JOURNAL OF BIOLOGICAL CHEMISTRY, (20070401), vol. 282, no. 15, doi:10.1074/jbc.M610879200, ISSN 0021-9258, pages 10901 - 10907, XP055040409 [A] 1-4,7-15 * the whole document *

DOI:   http://dx.doi.org/10.1074/jbc.M610879200
 [A]  - ANTONIO MACCHIARULO ET AL, "Expanding the horizon of chemotherapeutic targets: From MDM2 to MDMX (MDM4)", MEDCHEMCOMM, (20110101), vol. 2, no. 6, doi:10.1039/c0md00238k, ISSN 2040-2503, page 455, XP055040410 [A] 1-4,7-15 * the whole document *

DOI:   http://dx.doi.org/10.1039/c0md00238k
 [X]  - "SubName: Full=RNA polymerase II second largest subunit; Flags: Fragment;", UniProt, (20111019), Database accession no. G0TA93, URL: EBI, XP002699738 [X] 1-3 * the whole document *
by applicantWO0061193
 WO2008106507
 WO2011005219
    - SHANGARY S; WANG S., "Targeting the MDM2-p53 interaction for cancer therapy", CLIN CANCER RES., (20080901), vol. 14, no. 17, pages 5318 - 24
    - TOLEDO F; WAHL GM, "MDM2 and MDM4: p53 regulators as targets in anticancer therapy", INT J BIOCHEM CELL BIOL., (20070408), vol. 39, no. 7-8, doi:doi:10.1016/j.biocel.2007.03.022, pages 1476 - 82, XP022145785

DOI:   http://dx.doi.org/10.1016/j.biocel.2007.03.022
    - SHANGARY S; WANG S, "Targeting the MDM2-p53 interaction for cancer therapy", CLIN CANCER RES., (20080901), vol. 14, no. 17, pages 5318 - 24
    - CHEOK CF; VERMA CS; BASELGA J; LANE DP, "Translating p53 into the clinic", NAT REV CLIN ONCOL., (20101026), vol. 8, no. L, pages 25 - 37
    - RINALDO C; PRODOSMO A; MANCINI F; LACOVELLI S; SACCHI A; MORETTI F; SODDU S, "MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis", MOL CELL, (20070309), vol. 25, no. 5, pages 739 - 50
    - ASHCROFT M; TAYA Y; VOUSDEN KH, "Stress signals utilize multiple pathways to stabilize p53", MOL CELL BIOL, (2000), vol. 20, pages 3224 - 33
    - LATONEN L; TAYA Y; LAIHO M, "UV-radiation induces dose-dependent regulation of p53 response and modulates p53-HDM2 interaction in human fibroblasts", ONCOGENE, (2001), vol. 20, pages 6784 - 93
    - MENG LH; KOHN KW; POMMIER Y, "Dose- response transition from cell cycle arrest to apoptosis with selective degradation of Mdm2 and p21WAF1/CIP1 in response to the novel anticancer agent, aminoflavone (NSC 686,288", ONCOGENE, (2007), vol. 26, pages 4806 - 16
    - SHMUELI A; OREN M., "Mdm2: p53's lifesaver?", MOL CELL, (20070323), vol. 25, no. 6, pages 794 - 6
    - JACKSON MW; BERBERICH SJ, "MdmX protects p53 from Mdm2-mediated degradation", MOL CELL BIOL, (2000), vol. 20, doi:doi:10.1128/MCB.20.3.1001-1007.2000, pages 1001 - 7, XP055000959

DOI:   http://dx.doi.org/10.1128/MCB.20.3.1001-1007.2000
    - STAD R; LITTLE NA; XIRODIMAS DP; FRENK R; VAN DER EB AJ; LANE DP ET AL., "Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms", EMBO REP, (2001), vol. 2, pages 1029 - 34
    - MANCINI F; GENTILETTI F; D'ANGELO M; GIGLIO S; NANNI S; D'ANGELO C ET AL., "MDM4 (MDMX) over-expression enhances stabilization of stress-induced p53 and promotes apoptosis", J BIOL CHEM, (2004), vol. 279, pages 8169 - 80
    - BARBOZA JA; IWAKUMA T; TERZIAN T; EI-NAGGAR AK; LOZANO G, "Mdm2 and Mdm4 loss regulates distinct p53 activities", MOL CANCER RES, (2008), vol. 6, pages 947 - 54
    - SHMUELI A; OREN M, "Mdm2: p53's lifesaver?", MOL CELL, (20070323), vol. 25, no. 6, pages 794 - 6
    - MANCINI F; MORETTI F, "Mitochondrial MDM4 (MDMX): An unpredicted role in the p53-mediated intrinsic apoptotic pathway", CELL CYCLE, (200912), vol. 8, no. 23, pages 3854 - 9
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.